GlassScriptPhysician profile
Kerry L Drain
NPI 1710978630
$2,154.29
in general payments reported to CMS, 2019-2025
20 companies · $1,048 in 2025
The $1,048 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $87.57 · 2020: $34.94 · 2021: $118 · 2022: $306 · 2023: $200 · 2024: $360 · 2025: $1,048.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,574 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,573.58 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $377.61 | 2019-2025 | Airsupra, Fasenra, Tezspire |
| Glaxosmithkline, LLC. | $336.99 | 2019-2025 | Nucala, Trelegy Ellipta |
| Csl Behring | $158.97 | 2023-2025 | Andembry, Hizentra, Haegarda |
| Genzyme Corporation | $144.53 | 2023-2025 | |
| Genentech USA, INC. | $123.95 | 2019-2025 | Xolair |
| Biocryst US Sales Co., LLC | $118.05 | 2024-2025 | Orladeyo |
| Amgen INC. | $116.93 | 2024-2025 | Tezspire, Actimmune |
| Takeda Pharmaceuticals U.S.A., INC. | $109.14 | 2021-2025 | Gattex, Takhzyro |
| Novartis Pharmaceuticals Corporation | $100.15 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $73.59 | 2021-2025 | Dupixent |
| Pharming Healthcare, INC. | $72.03 | 2024-2025 | Ruconest |
| Bio Products Laboratory USA, INC. | $64.34 | 2022-2023 | Coagadex, Gammaplex |
| Blueprint Medicines Corporation | $62.73 | 2023-2025 | Ayvakit |
| Incyte Corporation | $52.35 | 2022-2025 | Opzelura |
| Pfizer INC. | $52.33 | 2022-2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $50.62 | 2022 | |
| Ars Pharmaceuticals Operations, INC. | $46.97 | 2025 | Neffy |
| Galderma Laboratories, L.P. | $40.91 | 2024-2025 | Nemluvio |
| Grifols USA, LLC | $27.00 | 2025 | Xembify |
| Octapharma USA, INC. | $25.10 | 2025 | Octagam Immune Globulin (Human) |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kerry Drain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.